AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04000672 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HTO with navigation
Description: In brief, an incision is made in the midway between posteromedial border of the tibia and medial aspect of the tibial tuberosity. Sartorius fascia is cut and retracted medially to expose the medial collateral ligament (MCL). Two to three K-wires are placed 4 cm below the medial joint line toward the safe zone (an area between the tip of the fibular head and the remnant of fibular head epiphysis line) of the lateral cortex under fluoroscopy and osteotomy is done below and parallel to the k-wires using an oscillating saw leaving the lateral 10 mm intact.
Study NCT04000672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HTO with navigation
Description: In brief, an incision is made in the midway between posteromedial border of the tibia and medial aspect of the tibial tuberosity. Sartorius fascia is cut and retracted medially to expose the medial collateral ligament (MCL). Two to three K-wires are placed 4 cm below the medial joint line toward the safe zone (an area between the tip of the fibular head and the remnant of fibular head epiphysis line) of the lateral cortex under fluoroscopy and osteotomy is done below and parallel to the k-wires using an oscillating saw leaving the lateral 10 mm intact.
Study NCT04056663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health-Circuit mobile application
Description: Health-Circuit as a collaborative tool between professionals and patient and professionals
Study NCT00819767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren was supplied in 150 mg tablets.
Study NCT00819767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan was supplied in 160 mg capsules.
Study NCT00819767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to aliskiren
Description: Placebo to aliskiren was supplied in tablets matching aliskiren 150 mg.
Study NCT00819767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to aliskiren
Description: Placebo to aliskiren was supplied in tablets matching aliskiren 150 mg.
Study NCT00819767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to valsartan
Description: Placebo to valsartan was supplied in capsules matching valsartan 160 mg.
Study NCT00819767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to valsartan
Description: Placebo to valsartan was supplied in capsules matching valsartan 160 mg.
Study NCT00942812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diarrhea Pack
Description: Low osmolality ORS, Zinc tablets, water purification tablets and pictorial chart
Study NCT00942812 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ORS
Description: ORS has been supplied to diarrheal cases as standard care through the LHW program at community level
Study NCT00776568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extra-corporeal shockwave
Description: Low intensity shock waves are applied as 300 shocks per visit for 09 visits. The treatment visit is carried at week 1, 5 and 9.
Study NCT00453505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: \<=1 Hz TMS for up to 30mins and up to 115% of resting motor threshold intensity (MT).
Study NCT00453505 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS
Description: \<=1 Hz TMS for up to 30mins and up to 115% of resting motor threshold intensity (MT).
Study NCT00453505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS up to 2 mA for up to 60mins.
Study NCT00453505 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: tDCS up to 2 mA for up to 60mins.
Study NCT00453505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS
Description: tACS up to 1 mA for up to 10 minutes.
Study NCT00453505 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tACS
Description: tACS up to 1 mA for up to 10 minutes.
Study NCT00453505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPNS
Description: CPNS alone with intensities below 130% of the peripherally-elicited-motor-threshold for up to 2 hours.
Study NCT00453505 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CPNS
Description: CPNS alone with intensities below 130% of the peripherally-elicited-motor-threshold for up to 2 hours.
Study NCT01562158 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: Standard treatment of bleeding
Study NCT01562158 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: standard therapy
Description: Standard treatment of bleeding
Study NCT01562158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: Two days repeated treatment regimen - low dose administered i.v. (into the vein)
Study NCT01609959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azilsartan
Description: Azilsartan 20 mg or 40 mg (if blood pressure does not reach the target after 6 weeks) per day for 12 weeks
Study NCT01609959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan 160 mg per day
Study NCT01038284 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Description: Pharmaceutical care of patients with PAH
Study NCT01562158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: Two days repeated treatment regimen - medium dose administered i.v. (into the vein)
Study NCT01562158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: Two days repeated treatment regimen - high dose administered i.v. (into the vein)
Study NCT01562158 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study NCT04166500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Description: outpatient hysteroscopy after the first menstrual cycle in the follicular phase (9-12 days).
Study NCT00920933 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Study NCT00920933 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00920933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone
Study NCT00776568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-hypertensive drugs
Description: ACE inhibitors, Ca channel blockers, Beta blockers, Diuretics, Cholesterol lowering agents and/or other drugs used alone or in combination, as prescribed.
Study NCT01554085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-002158
Description: ALS-002158
Study NCT01554085 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT01585870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Sorafenib (starting dose of 200 mg bid, level 1) administration will begin on Day 11 of Cycle 1, and will be administered twice daily continuously. If the combination is well tolerated, the dose will be escalated in new cohorts to 200 mg AM and 400 mg PM (level 2), then subsequently to 400 mg bid (level 3).~If sorafenib starting dose (level 1) is not well tolerated with eribulin, the sorafenib dose will be de-escalated to 200 mg qd (Dose Level -1) in a new cohort.
Study NCT01585870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin: 1.4 mg/m2 as an intravenous infusion on Days 1 and 8 of each 21-day cycle.
Study NCT06434428 — intervention group
Intervention type: DRUG
Intervention: dexmedetomidine (IV)
Description: Administration of IV dexmedetomidine
Study NCT06434428 — intervention group
Intervention type: DRUG
Intervention: dexmedetomidine (IN)
Description: Administration of IN dexmedetomidine
Study NCT01019577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, Maximum 9 cycles
Study NCT01049139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1-sided messages
Description: Supplemental information with 1-sided messages (emphasizes information content related to vaccine trial randomization and unproven efficacy of vaccine).
Study NCT01049139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2-sided messages
Description: Supplemental information with 2-sided messages (acknowledges the beliefs that are at odds with the information content and seeks to neutralize those beliefs through counter-argument).
Study NCT02664376 — intervention group
Intervention type: OTHER
Intervention: Sarcopenia detection
Description: The assessment of sarcopenia is performed according to the recommendations of the EWGSOP (European Working Group on Sarcopenia in Older people). Three measurements are made:~* Muscle mass measurement by dual energy X-ray absorptiometry (DEXA).~* Walking speed measurement~* Hand grip test~A diagnosis of sarcopenia is established if the walking speed is inferior to 0.8 m/sec, the muscular strength is low and the muscular mass is low.~Data regarding the geriatric characteristics of this sarcopenic population will be collected.
Study NCT04692948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor T cells (car-t)
Description: Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.
Study NCT02939001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iris recognition scanner
Study NCT00817050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate Nasal Spray
Description: One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray
Study NCT00817050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone nasal spray
Description: One dose (2 sprays in each nostril) of fluticasone nasal spray
Study NCT01772719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin and zoledronic acid
Description: 1. Simvastatin 80 mg PO daily starting two days before starting chemotherapy and stopping two days after chemotherapy.~2. Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly.
Study NCT04549051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tenex
Description: Local anesthetic plus Tenex into the coracohumeral ligament for adhesive capsulitis
Study NCT04549051 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Local anesthetic
Description: Only local anesthetic into the coracohumeral ligament for adhesive capsulitis
Study NCT04549051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local anesthetic
Description: Only local anesthetic into the coracohumeral ligament for adhesive capsulitis
Study NCT01038284 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Data collection
Description: Clinical and biological data, treatment, medication errors and ADEs
Study NCT02797106 — intervention group
Intervention type: OTHER
Intervention: Practice survey of health professionals
Description: Survey of the practices and opinions of health care professionals to describe care pathways, assessment and treatment of drooling in children with cerebral palsy
Study NCT00705224 — intervention group
Intervention type: BIOLOGICAL
Intervention: Pegylated Interferon
Description: Routine treatment with a combination of any pegylated interferon and ribavirin was used according to the label/local practice in Russia.~The treatment course duration complied with the labeled dosage regimen. Each dose of pegylated interferon was administered as a subcutaneous~injection calculated as 1.5 mcg/kg once a week. Therapy duration varied from 24 to 48 weeks depending on Hepatitis C virus (HCV) genotype, viral load, activity and stage of hepatitis C.~The Sponsor did not provide formal drug supply.
Study NCT00705224 — intervention group
Intervention type: DRUG
Intervention: Ribavirin
Description: Routine treatment with a combination of any pegylated interferon and ribavirin was used according to the label/local practice in Russia.~The treatment course duration complied with the labeled dosage regimen. Ribavirin was taken orally as 200 mg gelatinous capsules. The daily dose varied from 800 to 1200 mg (depending on patient's body weight) twice daily in the~morning and in the evening with meal. Therapy duration varied from 24 to 48 weeks depending on HCV genotype, viral load, activity and stage of hepatitis C.~The Sponsor did not provide formal drug supply.
Study NCT03809351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]AV-1451-PET
Description: All study participants will undergo brain imaging with \[F-18\]AV-1451-PET/MRI. \[F-18\]AV-1451 is a PET imaging agent used primarily to measure the amount of abnormal tau protein deposition the brain.
Study NCT01814358 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein powder
Description: Subjects on this arm will consume 20g whey protein powder mixed with water 15 minutes prior to breakfast, lunch, and dinner for two days
Study NCT01814358 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control protein
Description: Subjects on this arm will consume 20g gelatin protein powder mixed with water 15 minutes prior to breakfast, lunch, and dinner for two days
Study NCT02292550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: CDK 4/6 inhibitor
Study NCT02370732 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Alcohol
Description: A weight based dose of alcohol will be administered during each study day.
Study NCT02292550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: ALK inhibitor
Study NCT03867617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regulatory T cells
Description: Single infusion of expanded regulatory T cells.
Study NCT03867617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Treatment during first month post-transplant.
Study NCT03867617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone marrow
Description: Infusion of donor bone marrow cells.
Study NCT03867617 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kidney transplant
Description: Living donor kidney transplantation.
Study NCT03867617 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney transplant
Description: Living donor kidney transplantation.
Study NCT03867617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immunosuppressive drug therapy
Description: Immunosuppressive drug therapy.
Study NCT03867617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunosuppressive drug therapy
Description: Immunosuppressive drug therapy.
Study NCT02611427 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education/Self-efficacy
Description: The education/self-efficacy group will 1) receive information about benefits of physical activity and national activity guidelines, 2) receive instruction on how to increase lifestyle walking, 3) use movement monitoring devices, 4) make a walking contract and 5) receive interval contract-directed encouragement from study personnel.
Study NCT02611427 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: The education group will receive information about safe physical activity.
Study NCT02812966 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lutonix
Description: Drug Coated Balloons
Study NCT02812966 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IN.PACT
Description: Drug Coated Balloons
Study NCT02728245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest
Description: Dienogest 2mg po qd
Study NCT02728245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dienogest
Description: Dienogest 2mg po qd
Study NCT02728245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drug
Description: Placebo 1 table po qd
Study NCT02728245 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: conservative surgery without intent to oophorectomy
Study NCT02728245 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgery
Description: conservative surgery without intent to oophorectomy
Study NCT04639154 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Erector spinea plane block
Description: ESPPB will be performed at the T5 and T8 levels of the spine using an in-plane approach. A real-time ultrasound machine will be used to evaluate block performance. A high frequency linear ultrasound probe will be placed longitudinally at a distance of 3 cm from the midline. After identifying the erector spinae muscle and transverse processes, we will insert a 22 G, 100-mm needle after standard skin disinfection. It will be inserted in a caudal-to-cephalad direction using a sterile probe cover until the tip lay in the interfacial plane deep into the erector spinae muscle. This plane will be opened following hydrolocalization with normal saline then 30 mL of 0.25% bupivacaine will be injected slowly, with or without adjuvants, and aspirate every 5 ml to ensure block performance.
Study NCT04639154 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinea plane block
Description: ESPPB will be performed at the T5 and T8 levels of the spine using an in-plane approach. A real-time ultrasound machine will be used to evaluate block performance. A high frequency linear ultrasound probe will be placed longitudinally at a distance of 3 cm from the midline. After identifying the erector spinae muscle and transverse processes, we will insert a 22 G, 100-mm needle after standard skin disinfection. It will be inserted in a caudal-to-cephalad direction using a sterile probe cover until the tip lay in the interfacial plane deep into the erector spinae muscle. This plane will be opened following hydrolocalization with normal saline then 30 mL of 0.25% bupivacaine will be injected slowly, with or without adjuvants, and aspirate every 5 ml to ensure block performance.
Study NCT00418847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: miglustat
Description: Target dose of 320 mg/m\^2/day (divided in 3 doses) will be based on the Body Surface Area (BSA). For children with a BSA > 1.3, 200 mg TID will be administered. For children with a BSA of 0.8-1.3, 100 mg TID will be administered.
Study NCT02518711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Teacher Program
Description: This program was based on the evidence-based Summer Treatment Program (MTA Cooperative Group, 1999), involving psycho-education for the teacher and universal and individual behavioral techniques that focused on classroom structure and contingency management
Study NCT02008864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Senna
Description: (7.5 mg of sennosoides A and B) Senna tablet/ 2 times per day
Study NCT02008864 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet/ 2 times per day
Study NCT02714829 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inject BMP
Description: Injection of ExcelOS-inject(beta-TCP) containing rhBMP-2.
Study NCT02714829 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ExcelOS-inject
Description: Injection of ExcelOS-inject(beta-TCP) without rhBMP-2.
Study NCT03596424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hydrochloride
Description: Intraoperative bolus and infusion (see arm description)
Study NCT03596424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride
Description: Intraoperative bolus and infusion (see arm description)
Study NCT03596424 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine Hydrochloride and Ketamine Hydrochloride
Description: Intraoperative bolus and infusion (see arm description)
Study NCT02680769 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 300 mg of citrate Mg
Description: This group will take an oral supplementation of 300 mg of citrate magnesium
Study NCT02680769 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will take a placebo
Study NCT00695084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy
Description: Intensive practice with the hemiparetic arm for 30 contact hours
Study NCT03218293 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIPC device (IPC-906X)
Description: Patients in the RIPC group had five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm after thrombolysis.